Ostarine (Enobosarm) vs. RAD-140 (Testolone): A Comparative Analysis of Selective Androgen Receptor Modulators

Abstract

Selective Androgen Receptor Modulators (SARMs) were developed to provide the anabolic benefits of traditional androgenic-anabolic steroids (AAS) while minimizing detrimental effects on the prostate, skin, and hair. Enobosarm (Ostarine) and Testolone (RAD-140) represent two of the most researched compounds in this class. Ostarine is currently the most clinically validated SARM, with multiple Phase II and Phase III human trials focused on muscle wasting and sarcopenia. Conversely, RAD-140 is characterized by higher potency and unique neuroprotective properties in preclinical models, with more recent human clinical data emerging from oncology trials. This article compares their mechanisms of action, clinical efficacy, safety profiles, and pharmacokinetics based on currently available peer-reviewed literature.

Mechanism Comparison

Both Enobosarm and RAD-140 are non-steroidal ligands that bind to the androgen receptor (AR) with high affinity. They are designed to elicit tissue-selective activation, specifically targeting skeletal muscle and bone while acting as weak agonists or antagonists in the prostate and sebaceous glands.

• •Enobosarm (MK-2866): Functions as a full agonist in muscle and bone. It does not undergo 5-alpha reduction to dihydrotestosterone (DHT) nor aromatization into estrogen. Its selectivity is attributed to its ability to induce a specific conformational change in the AR that favors recruitment of co-activators in anabolic tissues over androgenic ones (Dalton et al., 2011).
• •Testolone (RAD-140): Demonstrates high binding affinity ($K_i$ of 7 nM) and exceptional selectivity. In animal models, RAD-140 has shown a higher ratio of anabolic-to-androgenic activity compared to testosterone propionate. Uniquely, RAD-140 exhibits neuroprotective effects by activating AR signaling pathways in neurons, which may protect against excitotoxic insults (Jayaraman et al., 2014). Like Enobosarm, it does not aromatize or undergo 5-alpha reduction.

Efficacy Comparison

The data regarding efficacy differs significantly in "strength of evidence," as Enobosarm has been subjected to larger human cohorts, whereas RAD-140 data is primarily derived from animal models and early-phase oncology trials.

| Compound | Primary Research Focus | Observed Efficacy | | :--- | :--- | :--- | | Enobosarm | Sarcopenia, Cancer Cachexia | Dose-dependent increase in lean body mass (LBM); improved stair-climb power in some cohorts. | | RAD-140 | Breast Cancer, Neuroprotection | Potent muscle weight increase in primates; tumor suppression in AR+/HER2- breast cancer. |

Enobosarm (Human Clinical Data)

In a pivotal Phase II double-blind, placebo-controlled study of 120 healthy elderly men and women, 3 mg of Enobosarm daily for 12 weeks resulted in a significant increase in lean body mass (mean 1.3 kg) and improved physical function (stair climb power). It also showed efficacy in patients with cancer cachexia, significantly increasing LBM compared to placebo (Dalton et al., 2011; Dobs et al., 2013).

RAD-140 (Preclinical & Early Human Data)

In preclinical studies involving orchidectomized rats, RAD-140 was found to be more anabolic than testosterone at lower doses while sparing the prostate. Primate studies (cynomolgus monkeys) showed a mean weight gain of over 10% in just 28 days of administration at doses as low as 0.1 mg/kg (Miller et al., 2011). Recent Phase I human data in postmenopausal women with breast cancer showed clinical benefit (stable disease or partial response) in a subset of patients, though muscle mass was not the primary endpoint (LoRusso et al., 2022).

Safety & Side Effect Comparison

Both compounds avoid the severe hepatotoxicity and erythrocytosis often associated with oral 17-alpha-alkylated steroids, but they are not without side effects.

• •Hormonal Suppression: Both compounds suppress the Hypothalamic-Pituitary-Testicular Axis (HPTA). In Enobosarm trials, dose-dependent reductions in serum testosterone, SHBG, and LH were observed, though levels typically returned to baseline post-treatment (Coss et al., 2016). RAD-140 has also shown significant suppression of total testosterone and SHBG in human Phase I trials (LoRusso et al., 2022).
• •Lipid Profile: Both SARMs tend to reduce High-Density Lipoprotein (HDL) cholesterol. Enobosarm studies consistently reported a decrease in HDL, which is a common class effect of AR agonists (Dalton et al., 2011).
• •Liver Enzymes: Transient elevations in alanine aminotransferase (ALT) have been reported for both. While usually asymptomatic, case reports of drug-induced liver injury (DILI) have surfaced in "real-world" recreational use of RAD-140, though these often involve unverified dosages or "stacking" with other substances (Koller et al., 2021).

Pharmacokinetics Comparison

| Feature | Enobosarm (MK-2866) | Testolone (RAD-140) | | :--- | :--- | :--- | | Half-Life ($t_{1/2}$) | ~24 hours | ~60 hours (Human) | | Administration | Oral (Daily) | Oral (Daily) | | Metabolism | Minimal hepatic metabolism | Extensive; multiple metabolites |

Enobosarm’s 24-hour half-life makes it ideal for once-daily dosing. Early animal studies suggested a shorter half-life for RAD-140, but recent human clinical data indicates a much longer terminal half-life of approximately 60 hours, suggesting that the compound may accumulate in the system more than Ostarine if dosed daily (LoRusso et al., 2022).

Research Limitations

1. •Regulatory Status: Neither compound is FDA-approved for human use outside of clinical trials. Both are on the WADA prohibited list.
2. •Lack of Long-Term Data: There are no multi-year studies on the cardiovascular or hepatic impact of long-term SARM use in humans.
3. •Endpoint Failures: While Enobosarm increased LBM in Phase III trials (POWER1 and POWER2), it failed to consistently meet the FDA's requirement for a statistically significant improvement in physical function (stair climb) across all populations, leading to hurdles in clinical approval.
4. •RAD-140 Data Scarcity: Most RAD-140 data stems from oncology populations or animal models; its effects on healthy human muscle and long-term safety remain largely uncharacterized in peer-reviewed literature.

References

1. •Coss, C. C., et al. (2016). "Physicochemical characterization and pharmacokinetics of enobosarm." Journal of Cachexia, Sarcopenia and Muscle, 7(2), 234-242. DOI: 10.1002/jcsm.12059
2. •Dalton, J. T., et al. (2011). "The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial." The Lancet Oncology, 12(9), 854-862. DOI: 10.1016/S1470-2045(11)70153-5
3. •Dobs, A. S., et al. (2013). "Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised, controlled phase 2 trial." The Lancet Oncology, 14(4), 335-345. DOI: 10.1016/S1470-2045(13)70055-X
4. •Jayaraman, A., et al. (2014). "Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned rats." Endocrinology, 155(4), 1398-1406. DOI: 10.1210/en.2013-1725
5. •Koller, T., et al. (2021). "Drug-induced liver injury associated with a selective androgen receptor modulator RAD140, a case report." Hepatology Communications, 5(6), 1104-1107. DOI: 10.1002/hep4.1654
6. •LoRusso, P., et al. (2022). "Phase 1 Study of RAD140, a Novel Selective Androgen Receptor Modulator, in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer." Clinical Cancer Research, 28(5), 858-866. DOI: 10.1158/1078-0432.CCR-21-2405
7. •Miller, C. P., et al. (2011). "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140." ACS Medicinal Chemistry Letters, 2(2), 124-129. DOI: 10.1021/ml1002508